Arnatar Therapeutics is a biopharmaceutical company that specializes in the development of novel nucleic acid medications.
Arnatar Therapeutics has raised $52.0M in total funding. The most recent round was Series A. The last funding was announced in April 2024.
Arnatar Therapeutics's investors include Gaorong Capital, Apricot Capital, Legend Star, F-Prime, 3E Bioventures.
Arnatar Therapeutics is headquartered in San Diego, United States.
Arnatar Therapeutics is a biopharmaceutical company that specializes in the development of novel nucleic acid medications.
Arnatar Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Arnatar Therapeutics — Funding & Investors." VCBacked, April 8, 2024, https://www.vcbacked.co/company/arnatar-therapeutics. Accessed November 13, 2026.
VCBacked. (2024). Arnatar Therapeutics — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/arnatar-therapeutics
{{cite web |title=Arnatar Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/arnatar-therapeutics |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Arnatar Therapeutics? Request a listing update